Skip to content
Screener

DexCom DXCM Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

American Electric Power logo
American Electric PowerAEP
$6.50
Stryker logo
StrykerSYK
$0.100.0%
Williams Companies logo
Williams CompaniesWMB
$1.000.0%
Rockwell Automation logo
Rockwell AutomationROK
$1.000.0%
SharkNinja logo
SharkNinjaSN
$0
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$00.0%

Other financials

Income statement

See full
Revenue$1.3B+13.1%
Gross profit$830.0M+20.5%
Operating income$318.3M+49.7%
Net income$249.1M+38.5%
EPS (diluted)$0.64+42.2%

Balance sheet

See full
Cash & equivalents$1.1B-4.8%
Total debt$103.3M-23.1%
Total equity$2.6B+1.9%
Total assets$6.5B-11.9%

Cash flow

See full
Operating cash flow$525.6M+186%
CapEx$76.6M-12.0%
Free cash flow$449.0M+364%

Valuation

See full
Market cap$31.98B+4.8%
Enterprise value$30.98B+5.0%
P/E32×-21.4×
P/S6.4×-0.7×

Profitability

See full
Gross margin62.5%+3.7pp
Operating margin22.9%+6.9pp
Net margin20.1%+6.8pp
FCF margin29.7%+15.8pp

Returns & leverage

See full
Return on equity38.5%+15.7pp
Debt / equity0.0×
Current ratio1.7×+0.2×

Where this comes from

Reported directly by DexCom in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: DexCom’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001093557-26-000073
(In millions, except share and par value data)March 31, 2026December 31, 2025
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.001 par value, 800.0 million shares authorized; 412.3 million and 385.9 million shares issued and outstanding, respectively, at March 31, 2026; and 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 20250.40.4
Additional paid-in capital2,337.52,281.5
Accumulated other comprehensive income106.2115.0
Retained earnings2,633.42,433.9
Treasury stock, at cost; 26.4 million shares at March 31, 2026 and 25.9 million shares at December 31, 2025(2,120.6)(2,084.8)

Item 1. Financial Statements

FAQ

What is DexCom's common stock, par value (in dollars per share)?
DexCom (DXCM) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has DexCom's common stock, par value (in dollars per share) changed year-over-year?
DexCom's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for DexCom's common stock, par value (in dollars per share)?
Over 4 years (2020 to 2025), DexCom's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Ask your AI about DexCom's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude